- Home
- Apac Leber Congenital Amaurosis Market
APAC Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-496 | No of pages: 202 | Format:
Asia-Pacific leber congential amaurosis market is projected to register a CAGR of 3.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific leber congential amaurosis market are:
Revolutionized genetic and molecular diagnosis
Increased rate of consanguinity in some Asian populations
Market Players:
The key market players for Asia-Pacific leber congential amaurosis market are listed below:
MeiraGTx Limited
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 22 1.1 OBJECTIVES OF THE STUDY 22 1.2 MARKET DEFINITION 22 1.3 OVERVIEW OF ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET 22 1.4 LIMITATIONS 23 1.5 MARKETS COVERED 24 2 MARKET SEGMENTATION 27 2.1 MARKETS COVERED 27 2.2 GEOGRAPHICAL SCOPE 28 2.3 YEARS CONSIDERED FOR THE STUDY 29 2.4 CURRENCY AND PRICING 29 2.5 DBMR TRIPOD DATA VALIDATION MODEL 30 2.6 MULTIVARIATE MODELLING 33 2.7 DISEASE TYPE LIFELINE CURVE 33 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34 2.9 DBMR MARKET POSITION GRID 35 2.10 MARKET END USER COVERAGE GRID 36 2.11 VENDOR SHARE ANALYSIS 37 2.12 SECONDARY SOURCES 38 2.13 ASSUMPTIONS 38 3 EXECUTIVE SUMMARY 39 4 PREMIUM INSIGHTS 42 4.1 PIPELINE ANALYSIS FOR ASIA PACIFIC LEBER CONGENTIAL AMAUROSIS MARKET 44 4.2 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 46 4.3 PESTEL ANALYSIS 49 4.4 PORTERS FIVE FORCES 50 5 EPIDEMIOLOGY 51 6 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 52 6.1 DRIVERS 54 6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 54 6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 57 6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 63 6.2 RESTRAINTS 64 6.2.1 LACK OF QUALIFIED PROFESSIONALS 64 6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 65 6.3 OPPORTUNITIES 66 6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 66 6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 66 6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 67 6.4 CHALLENGES 68 6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 68 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 68 7 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 69 7.1 OVERVIEW 70 7.2 INFANTILE TYPE 73 7.3 JUVENILE TYPE 73 7.4 OTHERS 74 8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 75 8.1 OVERVIEW 76 8.2 THERAPY 79 8.2.1 GENE THERAPY 80 8.2.1.1 LUXTURNA 80 8.2.2 RETINAL PROSTHETIC 80 8.2.3 NEUROPROTECTIVE AGENTS 80 8.2.3.1 VITAMIN A PALMITATE 81 8.2.3.2 DOCOSAHEXAENOIC ACID 81 8.2.3.3 LUTEIN 81 8.2.3.4 OTHERS 81 8.2.4 OTHERS 81 8.3 DIAGNOSIS 82 8.3.1 CLINICAL DIAGNOSIS 83 8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 83 8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 84 8.3.1.1.2 DARK ADAPTOMETRY (DA) 84 8.3.1.2 RETINAL IMAGING 84 8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 84 8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 85 8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 85 8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 85 8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 85 8.3.1.3 VISUAL FIELD TEST 85 8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 85 8.3.1.3.2 MANUAL FIELD TEST 85 8.3.1.4 CLINICAL EYE EXAMINATION 86 8.3.1.4.1 SLIT LAMP 86 8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 86 8.3.1.4.3 REFRACTION TEST 86 8.3.1.4.4 DILATION EXAM 86 8.3.1.5 OTHERS 86 8.3.2 GENETIC DIAGNOSIS 87 9 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 88 9.1 OVERVIEW 89 9.2 HOSPITALS 92 9.3 SPECIALITY CLINICS 93 9.4 AMBULATORY SURGICAL CENTERS 94 9.5 HOME HEALTHCARE 95 9.6 OTHERS 96 10 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 97 10.1 OVERVIEW 98 10.2 RETAIL SALES 101 10.2.1.1 HOSPITAL PHARMACIES 102 10.2.1.2 RETAIL PHARMACIES 102 10.2.1.3 OTHERS 102 10.3 DIRECT TENDER 102 11 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 103 11.1 ASIA-PACIFIC 104 11.1.1 CHINA 112 11.1.2 JAPAN 116 11.1.3 INDIA 120 11.1.4 SOUTH KOREA 124 11.1.5 AUSTRALIA 128 11.1.6 SINGAPORE 132 11.1.7 THAILAND 136 11.1.8 INDONESIA 140 11.1.9 PHILIPPINES 144 11.1.10 MALAYSIA 148 11.1.11 VIETNAM 153 11.1.12 REST OF ASIA-PACIFIC 157 12 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 158 12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 158 13 SWOT ANALYSIS 159 14 COMPANY PROFILE 160 14.1 SPARK THERAPEUTICS, INC 160 14.1.1 COMPANY SNAPSHOT 160 14.1.2 COMPANY SHARE ANALYSIS 160 14.1.3 PRODUCT PORTFOLIO 161 14.1.4 RECENT DEVELOPMENT 161 14.1.4.1 EU AUTHORIZATION 161 14.2 OPTOS 162 14.2.1 COMPANY SNAPSHOT 162 14.2.2 COMPANY SHARE ANALYSIS 162 14.2.3 PRODUCT PORTFOLIO 163 14.2.4 RECENT DEVELOPMENT 163 14.2.4.1 PRODUCT APPROVAL 163 14.3 CD GENOMICS 164 14.3.1 COMPANY SNAPSHOT 164 14.3.2 COMPANY SHARE ANALYSIS 164 14.3.3 PRODUCT PORTFOLIO 165 14.3.4 RECENT DEVELOPMENT 165 14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 166 14.4.1 COMPANY SNAPSHOT 166 14.4.2 REVENUE ANALYSIS 166 14.4.3 COMPANY SHARE ANALYSIS 167 14.4.4 PRODUCT PORTFOLIO 167 14.4.5 RECENT DEVELOPMENTS 167 14.4.5.1 COLLABORATION 167 14.5 LKC TECHNOLOGIES, INC 168 14.5.1 COMPANY SNAPSHOT 168 14.5.2 COMPANY SHARE ANALYSIS 168 14.5.3 PRODUCT PORTFOLIO 169 14.5.4 RECENT DEVELOPMENT 169 14.5.4.1 PRODUCT APPROVAL 169 14.5.5 PRODUCT APPROVAL 169 14.6 AGTC 170 14.6.1 COMPANY SNAPSHOT 170 14.6.2 REVENUE ANALYSIS 170 14.6.3 PRODUCT PORTFOLIO 171 14.6.4 RECENT DEVELOPMENTS 171 14.6.4.1 AGREEMENT 171 14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 172 14.7.1 COMPANY SNAPSHOT 172 14.7.2 REVENUE ANALYSIS 172 14.7.3 PRODUCT PORTFOLIO 173 14.7.4 RECENT DEVELOPMENTS 173 14.8 ASTELLAS PHARMA INC. 174 14.8.1 COMPANY SNAPSHOT 174 14.8.2 REVENUE ANALYSIS 174 14.8.3 PRODUCT PORTFOLIO 175 14.8.4 RECENT DEVELOPMENT 175 14.9 ATSENA THERAPEUTICS 176 14.9.1 COMPANY SNAPSHOT 176 14.9.2 PRODUCT PORTFOLIO 176 14.9.3 RECENT DEVELOPMENT 176 14.10 CENTOGENE N.V. 177 14.10.1 COMPANY SNAPSHOT 177 14.10.2 REVENUE ANALYSIS 177 14.10.3 PRODUCT PORTFOLIO 178 14.10.4 RECENT DEVELOPMENT 178 14.10.4.1 PRODUCT LAUNCH 178 14.11 COAVE THERAPEUTICS 179 14.11.1 COMPANY SNAPSHOT 179 14.11.2 PRODUCT PORTFOLIO 179 14.11.3 RECENT DEVELOPMENT 179 14.12 EDITAS MEDICINE 180 14.12.1 COMPANY SNAPSHOT 180 14.12.2 REVENUE ANALYSIS 180 14.12.3 PRODUCT PORTFOLIO 181 14.12.4 RECENT DEVELOPMENTS 181 14.12.4.1 DATA & TRAIL DATA PRESENTATION 181 14.13 ELUMINEX BIOSCIENCES 182 14.13.1 COMPANY SNAPSHOT 182 14.13.2 PRODUCT PORTFOLIO 182 14.13.3 RECENT DEVELOPMENT 182 14.14 GYROSCOPE THERAPEUTICS LIMITED 183 14.14.1 COMPANY SNAPSHOT 183 14.14.2 PRODUCT PORTFOLIO 183 14.14.3 RECENT DEVELOPMENTS 183 14.15 INVITAE CORPORATION 185 14.15.1 COMPANY SNAPSHOT 185 14.15.2 REVENUE ANALYSIS 185 14.15.3 PRODUCT PORTFOLIO 186 14.15.4 RECENT DEVELOPMENTS 186 14.15.4.1 NEW FACILITY 186 14.15.4.2 EXPANSION 186 14.16 IVERIC BIO. 187 14.16.1 COMPANY SNAPSHOT 187 14.16.2 PRODUCT PORTFOLIO 187 14.16.3 RECENT DEVELOPMENT 187 14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 188 14.17.1 COMPANY SNAPSHOT 188 14.17.2 REVENUE ANALYSIS 188 14.17.3 PRODUCT PORTFOLIO 189 14.17.4 RECENT DEVELOPMENTS 189 14.18 MEIRAGTX LIMITED 190 14.18.1 COMPANY SNAPSHOT 190 14.18.2 PRODUCT PORTFOLIO 190 14.18.3 RECENT DEVELOPMENT 190 14.19 METROVISION 192 14.19.1 COMPANY SNAPSHOT 192 14.19.2 PRODUCT PORTFOLIO 192 14.19.3 RECENT DEVELOPMENT 192 14.19.3.1 FDA CLEARANCE APPROVAL 192 14.20 OCUGEN INC. 193 14.20.1 COMPANY SNAPSHOT 193 14.20.2 PRODUCT PORTFOLIO 193 14.20.3 RECENT DEVELOPMENT 193 14.21 OKUVISION 194 14.21.1 COMPANY SNAPSHOT 194 14.21.2 PRODUCT PORTFOLIO 194 14.21.3 RECENT DEVELOPMENTS 194 14.21.3.1 APPROVAL 194 14.22 PROQR THERAPEUTICS 195 14.22.1 COMPANY SNAPSHOT 195 14.22.2 PRODUCT PORTFOLIO 195 14.22.3 RECENT DEVELOPMENTS 195 14.23 REGENXBIO INC. 196 14.23.1 COMPANY SNAPSHOT 196 14.23.2 REVENUE ANALYSIS 196 14.23.3 PRODUCT PORTFOLIO 197 14.23.4 RECENT DEVELOPMENTS 197 14.24 SPARINGVISION 198 14.24.1 COMPANY SNAPSHOT 198 14.24.2 PRODUCT PORTFOLIO 198 14.24.3 RECENT DEVELOPMENTS 198 15 QUESTIONNAIRE 199 16 RELATED REPORTS 202Segmentation
Short Description Asia-Pacific Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029 Market Definition: Leber congenital amaurosis (LCA) is defined as a type of disorder of the eye which mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for the detection of light and colour. Leber congenital amaurosis (LCA) is a rare inherited eye disease that appears at birth or in the first few months of life. It affects about 1 in 40,000 new-borns. People with this disorder typically have severe visual impairment beginning in infancy. The visual impairment tends to be stable, although it may worsen very slowly over time. Market Segmentation: Asia-Pacific leber congential amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel. On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others. On the basis of type, the congenital amaurosis market is segmented into diagnosis and therapy. On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others. On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others. Market Players The key market players for Asia-Pacific leber congential amaurosis market are listed below: Invitae Corporation Spark Therapeutics, Inc., LKC TECHNOLOGIES, INC, CENTOGENE N.V., Optos, Metrovision, Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. Atsena Therapeutics Editas Medicine Eluminex Biosciences Okuvision Astellas Pharma Inc. Allergan (A Subsidiary of Abbvie Inc.) AGTC Gyroscope Therapeutics Limited SparingVision Kubota Pharmaceutical Holdings Co. Ltd. REGENXBIO IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.